First Trust Exchange-Traded Fund VIII Reports Financial Update

First Trust Exchange-Traded Fund VIII Reports Financial Update (FIRST TRUST EXCHANGE-TRADED FUND VIII)

First Trust Exchange-Traded Fund VIII has released its latest financial report, disclosing total assets of approximately $51.59 million as of August 31, 2026. This update is significant as it showcases the fund's management strategies and its position within the investment sector.

The filing, made on October 21, 2026, provides insights into the fund's financial health and investment strategies. The report indicates total liabilities of $42,512, leading to net assets of about $51.55 million. Such disclosures are crucial for investors and stakeholders, as they reflect the fund's performance and operational efficiency.

Background

First Trust Exchange-Traded Fund VIII, categorized under the investment entity type, operates within the investment management industry. The fund is based in Wheaton, Illinois, and is registered with the SEC under the file number 811-23147. The latest filing is part of a series of submissions, with additional filings occurring shortly after on October 26, 2026.

What the Filing Says

The NPORT-P filing reveals that the fund's total assets stand at $51,594,217.29, while total liabilities are reported at $42,512.00. The net assets are calculated to be $51,551,705.29. This financial snapshot is important for understanding the fund's current standing and future potential.

Impact

This financial update may influence various stakeholders, including investors, analysts, and competitors within the investment management sector. The reported figures provide a benchmark for assessing the fund's performance relative to its peers, which include companies like Xenon Pharmaceuticals Inc., Edgewise Therapeutics Inc., and FirstCash Holdings Inc., all of which are part of the fund's investment portfolio.

What's Next

Following this filing, additional reports are expected, as indicated by the upcoming NPORT-P filings scheduled for October 26, 2026. These subsequent disclosures will likely provide further insights into the fund's performance and investment strategies.

Source: SEC Accession Number 0000940400-26-040943